ERYTech Pharma SA Sponsored ADR

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.

ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal

ERYTECH to Present at the 12 th Annual Jefferies Global London Healthcare Conference In-Person Dates: November 16 th -17 th Virtual Dates: November 18 th -19 th

ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference

ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer

ERYTECH Announces M aximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer

ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech

ERYTECH Announces the A vailability of its H alf- Y ear F inancial R eport 202 1

ERYTECH Announces the Availability of its Half-Year Financial Report 2021

ERYTECH Pharma S.A.'s (ERYP) CEO Gil Beyen on Q2 2021 Results - Earnings Call Transcript

ERYTECH Provides Business Update and Reports Financial Results for the First Half of 20 2 1

ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021

ERYTECH t o Host on September 21, 2021 Second Quarter 2021 conference call and Business Update

ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update

Cambridge, MA (U.S.) and Lyon (France), September 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its CEO, Gil Beyen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The Conference will be held virtually with all participants joining remotely from September 13th - 15th, 2021.

ERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

ERYTECH to Participate in the Citi 16 th Annual BioPharma Conference

ERYTECH to Participate in the Citi 16th Annual BioPharma Conference

ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer

The stock price of ERYTECH Pharma (Nasdaq: ERYP) increased by over 10% pre-market. These are some details you should know.

ERYP Stock Increases Over 10% Pre-Market: Why It Happened

The stock price of ERYTECH Pharma SA (NASDAQ: ERYP) increased by over 130% during intraday trading. This is why it happened.

ERYP Stock Increases Over 130% Intraday: Why It Happened

ERYP stock is seeing a surge in value this morning, as it lands FDA fast track designation for its eryaspase treatment for a second time. The post ERYP Stock: The Huge FDA News That Has Little-Known Erytech Skyrocketing appeared first on InvestorPlace.

ERYP Stock: The Huge FDA News That Has Little-Known Erytech Skyrocketing

Erytech Pharma SA (NASDAQ: ERYP) is surging higher Friday morning after the company announced its eryaspase was granted U.S. FDA Fast Track designation. The Fast Track designation is for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E.

Why Erytech Pharma's Stock Is Surging Higher Today

Erytech Pharma SA (NASDAQ: ERYP) is surging higher in after hours trading after the company announced its eryaspase was granted U.S. FDA Fast Track designation. The Fast Track designation is for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E.

Why Erytech Pharma Shares Are Soaring Today

ERYTECH Granted U.S. FDA Fast Track Designation  for E ryaspase in Hypersensitive ALL

ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL

ERYTECH to Participate in the BTIG Virtual Biotechnology Conference

ERYTECH Confirms Plans To Submit BLA for E ryaspase in H ypersensitive ALL Patients

ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients

REPORT - ERYTECH'S COMBINED SHAREHOLDERS' MEETING ON JUNE 25, 2021

Report - Erytech's Combined Shareholders' Meeting on June 25, 2021

ERYTECH to Participate in Upcoming Virtual Investor Conferences in June

ERYTECH'S COMBINED SHAREHOLDERS' MEE TING

Erytech's Combined Shareholders' Meeting on June 25, 2021

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2021 Results - Earnings Call Transcript

ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 20 2 1

News for ERYTech Pharma SA Sponsored ADR Stock (ERYP)